Results 211 to 220 of about 3,681,633 (268)

In vivo site-specific engineering to reprogram T cells. [PDF]

Nature
Nyberg WA, Bernard PL, Ngo W, Wang CH, Ark J, Rothrock A, Borgo GM, Kimmerly GR, Jung JH, Allain V, Hamilton JR, Baldwin A, Stickels R, Wyman S, Khan SH, Lang S, Marsh D, Almudhfar N, Novick C, Mortazavi Y, Zhang S, AbdElwakil MM, Sandoval LR, Hwang S, Chu SN, Jung H, Liu C, Sharma D, McCreary T, Li Z, Satpathy AT, Carnevale J, Rutishauser RL, Cromer MK, Roybal KT, Dodgson SE, Doudna JA, Asokan A, Eyquem J.   +38 more
europepmc   +1 more source

Immunological Interactions Between Gammadelta T Cells and West Nile Virus in the Infected Host. [PDF]

Rev Med Virol
Cimini E, Tartaglia E, Cristofanelli F, Gili S, Maggi F.   +4 more
europepmc   +1 more source

Clonal dynamics of HIV-infected and uninfected T cells. [PDF]

EBioMedicine
Weissman S, Ginda AM, Oceguera A, Swiggard L, Pinzone M, Cannon L, Zurakowski R, Migueles S, Bushman FD, O'Doherty U.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The T Cell Receptor

Science, 1987
The primary structure of T cell receptor proteins and genes is well understood. Immunologists are now trying to understand the properties of these interesting molecules. Evidence suggests that T cell αβ receptors recognize a complex of an antigen-derived peptide bound to one of the cell-surface products of the major histocompatibility complex (MHC ...
P, Marrack, J W, Kappler
openaire   +3 more sources

CAR T Cells

2020
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire   +3 more sources

T-cell therapies for T-cell lymphoma

Cytotherapy, 2019
T-cell lymphomas represent a subpopulation of non-Hodgkin lymphomas with poor outcomes when treated with conventional chemotherapy. A variety of novel agents have been introduced as new treatment strategies either as first-line treatment or in conjunction with chemotherapy. Immunotherapy has been demonstrated to be a promising area for new therapeutics,
Keri Toner, Catherine M. Bollard, Hema Dave   +2 more
openaire   +2 more sources